Suppr超能文献

腹内及腹壁硬纤维瘤病

Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis.

作者信息

Howard J Harrison, Pollock Raphael E

机构信息

Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, M256 Starling Loving Hall, 320 W. 10th Ave, Columbus, OH 43210 USA.

出版信息

Oncol Ther. 2016;4(1):57-72. doi: 10.1007/s40487-016-0017-z. Epub 2016 Feb 3.

Abstract

Desmoid fibromatosis is a rare but locally aggressive tumor comprised of myofibroblasts. Desmoids do not have the ability to metastasize but can cause significant morbidity and mortality by local invasion. These tumors may occur throughout the body, but are commonly found on the abdominal wall and within the intestinal mesentery. Desmoids in these areas may cause unique clinical problems for physicians and patients. Mutations in either the β-catenin or the genes are usually the cause for the development of these tumors with the former comprising the sporadic development of tumors and the latter being associated with familial adenomatous polyposis syndrome. Surgical resection with histologically negative margins has been the cornerstone of therapy for this disease, but this paradigm has begun to shift. It is now common to accept a microscopically positive margin after resection as recurrence rates may not be significantly affected. An even more radical evolution in management has been the recent movement towards "watchful waiting" when new desmoids are diagnosed. As the natural history of desmoids has become better understood, it is evident that some tumors will not grow and may even spontaneously regress sparing patients the morbidity of more aggressive therapy. Other modalities of treatment for desmoids include radiation and systemic therapy which both can be used adjuvantly or as definitive therapy and have shown durable response rates as single therapy regimens. The decision to use radiation and/or systemic therapies is often based on tumor biology, tumor location, surgical morbidity, and patient preference. Systemic therapy options have increased to include hormonal therapies, non-steroidal anti-inflammatory drugs and chemotherapy, as well as targeted therapies. Unfortunately, the rarity of this disease has resulted in a scarcity of randomized trials to evaluate any of these therapies emphasizing the need for this disease to be treated at high volume multidisciplinary institutions.

摘要

硬纤维瘤病是一种罕见但具有局部侵袭性的肿瘤,由肌成纤维细胞组成。硬纤维瘤没有转移能力,但可通过局部侵袭导致严重的发病率和死亡率。这些肿瘤可发生于全身,但常见于腹壁和肠系膜内。这些部位的硬纤维瘤可能给医生和患者带来独特的临床问题。β-连环蛋白或某些基因的突变通常是这些肿瘤发生的原因,前者导致肿瘤的散发性发生,后者与家族性腺瘤性息肉病综合征相关。手术切除且切缘组织学阴性一直是该疾病治疗的基石,但这种模式已开始转变。现在普遍接受切除后显微镜下切缘阳性,因为复发率可能不会受到显著影响。治疗管理中更激进的演变是最近在诊断出新的硬纤维瘤时倾向于“观察等待”。随着对硬纤维瘤自然病程的了解越来越深入,很明显一些肿瘤不会生长,甚至可能自发消退,使患者避免了更积极治疗带来的发病率。硬纤维瘤的其他治疗方式包括放疗和全身治疗,这两种治疗都可作为辅助治疗或确定性治疗使用,并且作为单一治疗方案已显示出持久的缓解率。决定使用放疗和/或全身治疗通常基于肿瘤生物学、肿瘤位置、手术发病率和患者偏好。全身治疗选择已增加到包括激素治疗、非甾体抗炎药和化疗以及靶向治疗。不幸的是,这种疾病的罕见性导致缺乏评估这些治疗方法的随机试验,强调了在大型多学科机构治疗这种疾病的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验